Compare Ascendis Pharma A/S (ASND) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs United States Natural Gas Fund — how do they compare? Ascendis Pharma A/S trades at $257.91 (market cap $16.67B), while United States Natural Gas Fund trades at $10.21. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| ASND | UNG | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Commodities - Energy |
52-Week High | $277.18 | $16.90 |
52-Week Low | $189.74 | $9.63 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
UNG, tracking U.S. natural gas futures, trades at $10.24 with a 0.99% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights steady natural gas prices amid weather-driven demand shifts and geopolitical tensions. The fund lacks traditional company fundamentals as it is an ETF, with financial ratios unavailable.
The outlook is cautious due to bearish technicals and volatile commodity exposure. Opportunities exist if natural gas demand surges from weather or LNG exports, but risks include price swings from storage levels and production changes. Investors should weigh this as a speculative play on energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
